JP Morgan Healthcare Conference | Biomedtracker | Pharma Intelligence

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


2017 JP Morgan Conference Review
January 18, 2017

The 35th annual JP Morgan Healthcare Conference was held in San Francisco, CA from January 9-12, 2017. A full list of events and catalysts that were announced or updated during the conference is included in this report. Below are select key points from the conference’s company presentations.

Please fill in the form at the bottom of this page to access the report.

Key points in this report:

The meeting kicked off with the blockbuster announcement that Takeda will acquire Ariad (ARIA) and its oncology portfolio for approximately $5.2b. In March 2016, Takeda announced its strategic roadmap where it placed the oncology, gastroenterology, and central nervous system (CNS) franchises as its top R&D priority moving forward.

Merck (MRK) released a surprising disclosure that it had filed an sBLA for Keytruda in combination with chemotherapy for first-line NSCLC. The filing was surprising in its reliance on the Phase I/II KEYNOTE-021 study rather than the larger Phase III ‘189 study already ongoing for May 10, 2017.

Surprisingly, the new CEO of Biogen (BIIB) spent little time discussing any potential differentiators for aducanumab in Alzheimer’s disease following the high-profile failure of LLY’s solanezumab.


Intra-Cellular Therapies (ITCI) provided an update on its expected meeting with FDA regarding Lumateperone (ITI-007) for the treatment of schizophrenia, but was surprisingly quiet on the Phase III development of ITI-007 for the treatment of agitation in patients with dementia including Alzheimer’s disease.

Incyte (INCY) provided a roadmap for its main revenue driver, Jakafi. Specifically, officials seemed excited about advancing its development for GvHD and essential thrombocytopenia. Baricitinib will be the next revenue driver, according the the CEO, with a focus on psoriatic arthritis.

Moderna, a privately held company dedicated to developing messenger RNA (mRNA) vaccines and therapeutics, disclosed several development candidates advancing in its growing pipeline.


Editas (EDIT) announced that it achieved the first in vivo proof-of-editing in the retina of non-human primates in the LCA10 gene editing program for Leber’s Congenital Amaurosis.

Sarepta (SRPT) recorded $5.4 million in sales of Exondys 51 in the fourth quarter of 2016 and has received over 250 genetically verified start forms, providing some reassurance to the market about the muscular dystrophy drug's launch, given questions whether the FDA should have approved it in the first place.

View more key points from the entire conference in our full report. To access this, please fill in the form below.
Icon 1